USPTO serial 79314148
H.F.M BY TICEBA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 24, 2023
- Examiner
- BLANE, SUZANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with H.F.M BY TICEBA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sean K. Owens
Sean K. Owens WOOD HERRON & EVANS LLP441 Vine Street2700 Carew TowerCincinnati, OH 45202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for scientific or research use; cell growth media for growing cells for scientific use | ACTIVE | — |
| 005 | Pharmaceutical drugs, namely, pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; Pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; Pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing; Pharmaceutical preparations for anti-aging; Diagnostic agents for medical use; Preparations for medical purposes, namely, for the treatment of skin diseases; Substances for medical use, namely, for regeneration of tissue and anti-inflammation; Stem cells for medical purposes; Stem cells for veterinary purposes; Stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; Somatic stem cell therapeutics, namely, for medical therapeutic use; Fibroblasts for medical use; Fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; Pharmaceutical implants, namely, implantable surgery bones, bone grafts, cells, bone marrow; Surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; Surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; Biological tissue for implantation, namely, implants comprising living tissues; Cell growth media for growing cells for medical use; Pharmaceutical preparations for tissue regeneration; Vascular grafts; Living tissue, namely, surgical implants comprised of living tissues; Biotechnologically engineered tissue products, namely, cell sheets/plasters for wound healing/burns, eye lense grafts, bone grafts, biological tissue grafts, human allograft tissue | ACTIVE | — |
| 042 | Stem cell research; scientific research and development and medical research and development in the field of stem cells; Scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering; Scientific research for medical purposes; Medical research; Research and development of new products for others; Consultancy in the field of pharmaceutical research; Providing information on medical and scientific research on pharmaceutical products; Biomedical research; Preparation of reports relating to scientific research, namely, technical writing for others; Research in the field of biotechnology; Research in the field of gene therapy; Research and development in the field of immunology; Research and development in the field of antibodies; Research and development in the field of antibody technology; Research and development in the field of bacteriology; Research and development in the field of gene expression systems; Research and development in the field of vaccines; Research and development services for the pharmaceutical industry; Research and development services in the field of biotechnology; Development of industrial processes, namely, engineering of industrial processes to manufacture stem cells; Development of industrial processes, namely, in the field of regenerative medicine and tissue engineering;Industrial process research in the field of regenerative medicine, tissue engineering, chemical engineering | ACTIVE | — |
| 044 | Medical services relating to the removal, treatment, processing and preservation of medical cells and human tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named H.F.M BY TICEBA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 23, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 1, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 1, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 24, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 24, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 24, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 20, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 30, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 30, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 8, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 8, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 7, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 19, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 19, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 19, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 29, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 29, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 29, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 29, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 9, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 9, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jul 13, 2022 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jul 13, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2022 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jul 13, 2022 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jul 13, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 13, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 15, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 28, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 28, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 2, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 1, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 30, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 2, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 28, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 25, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |